摘要
淋系血液肿瘤患者感染新型冠状病毒后的预后较差,接种新型冠状病毒疫苗后的血清阳性率低于健康人群。由于绝大多数新型冠状病毒疫苗临床试验未纳入免疫缺陷人群,淋系血液肿瘤患者接种各类新型冠状病毒疫苗的安全性和有效性尚不明确。因此,医生应在充分考虑患者免疫状态、接受的治疗模式、感染新型冠状病毒的风险等因素后,决定淋系血液肿瘤患者是否需要接种疫苗及接种疫苗的时机、类型和剂次。
Patients with lymphoid hematologic malignancies have a poor prognosis after developing SARS-CoV-2 infection,and their seropositivity rate after SARS-CoV-2 vaccination is lower than that of the healthy population.Since most clinical trials of SARS-CoV-2 vaccines do not include immunodeficient populations,the safety and efficacy of various types of SARS-CoV-2 vaccines for patients with lymphoid hematologic malignancies are unclear.Therefore,physicians should decide whether patients with lymphoid hematologic malignancies receive SARS-CoV-2 vaccination and the timing,type and dose of vaccine after taking into full consideration the patient's immune status,type of treatment and the risk of SARS-CoV-2 infection.
作者
焦亚薇
陈舒亭
戴海萍
Jiao Yawei;Chen Shuting;Dai Haiping(Suzhou Medical College of Soochow University,Suzhou 215123,China;Department of Hematology,the First Affiliated Hospital of Soochow University,National Clinical Research Center for Hematologic Diseases,Jiangsu Institute of Hematology,Collaborative Innovation Center of Hematology,Hematopoietic Stem Cell Transplantation Institute of Soochow University,Suzhou 215006,China)
出处
《白血病．淋巴瘤》
CAS
2023年第4期249-252,共4页
Journal of Leukemia & Lymphoma
关键词
冠状病毒感染
淋系血液肿瘤
新型冠状病毒疫苗
Coronavirus infections
Lymphoid hematologic malignancies
SARS-CoV-2 vaccines
